acute myelocytic leukemia
Conditions
Interventions
Experimental group:Palbociclib in combination with Venetoclax and Azacitidine
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1.A clear diagnosis of AML. 2.Age 0-18 years. 3.Primary patients with positive NUP98-R fusion gene who are not in remission after one course of chemotherapy. 4.Refractory or relapsed patients with positive NUP98-R fusion gene. 5.Obtain the consent of the child or/and guardian and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Acute promyelocytic leukemia. 2.AML transformed by MDS. 3.AML secondary to Fanconi anemia. 4.AML secondary to Kostmanne's syndrome. 5.AML secondary to Shwachman syndrome. 6.AML secondary to other bone marrow failure disorders. 7.Only temporary chemotherapy or immunotherapy, without receiving systemic treatment in accordance with the treatment protocol. 8.With any significant abnormalities of coexisting diseases or psychiatric disorders that affect the patient's life safety and compliance, informed consent, study participation, follow-up or interpretation of result
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate after one course of VAP regimen treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| MRD levels after one course of VAP regimen treatment;Remission rate and MRD level after two courses of VAP regimen treatment;Recurrence rate within three years after remission;Three year overall survival and event free survival; | — |
Countries
China
Contacts
Public ContactRunming Jin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed